Chronic active Epstein-Barr virus infection treated with PEG-aspargase: A case report

doi:10.12998/wjcc.v9.i26.7845

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2559)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

236

WORD

115

HTML

1464

Figures (1-1)

165

Sum=1980

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

258

Download

321

Sum=579

Sep 16, 2021 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Sep 16, 2021; 9(26): 7845-7849
Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7845

Open in New Tab Full Size Figure Download Figure

Figure 1 Graph of the Epstein-Barr virus-DNA change trend of the patient after PEG-aspargase treatment. There is a significant decrease after the first PEG-aspargase treatment. After the third course of treatment, the patient's Epstein-Barr virus-DNA (EBV-DNA) turned negative (according to our hospital test standard, EBV-DNA < 500 copies/mL is negative). The arrow indicates the time of for PEG-aspargase treatment. EBV: Epstein-Barr virus.

Citation: Song DL, Wang JS, Chen LL, Wang Z. Chronic active Epstein-Barr virus infection treated with PEG-aspargase: A case report. World J Clin Cases 2021; 9(26): 7845-7849
URL: https://www.wjgnet.com/2307-8960/full/v9/i26/7845.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i26.7845